A study to assess the bioequivalence of fixed dose combination of dapagliflozin/metformin XR relative to co-administration of the individual components in healthy Chinese subjects.

Trial Identifier: D1691C00011
Sponsor: AstraZeneca
NCTID:: NCT04856007
Start Date: April 2021
Primary Completion Date: June 2021
Study Completion Date: June 2021
Condition: Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Simplified Chinese Translation

Trial Locations

Country Location
China Suzhou, China, 215006